These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35285291)

  • 21. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
    Veve MP; Wagner JL
    Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.
    Felix TM; Karpa K
    Am Fam Physician; 2020 Sep; 102(6):373-374. PubMed ID: 32931220
    [No Abstract]   [Full Text] [Related]  

  • 24. Development, validation, and application of an LC-MS/MS method for the quantification of the novel antibiotic drug lefamulin (Xenleta®) and its main metabolite 2R-hydroxy lefamulin in human plasma.
    Strickmann DB; Faber J; Klaassen T
    J Pharm Biomed Anal; 2021 Oct; 205():114293. PubMed ID: 34464869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lefamulin (Xenleta) for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
    Wicha WW; Strickmann DB; Paukner S
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue Distribution of [
    Wicha WW; Henson C; Webbley K; Gelone SP
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0035522. PubMed ID: 35862748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lefamulin for Treating Community-acquired Bacterial Pneumonia in Adult Patients Aged <65 Years.
    Tang HJ; Lai CC
    Clin Infect Dis; 2020 Sep; 71(6):1582. PubMed ID: 31822903
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model.
    Hafner M; Paukner S; Wicha WW; Hrvačić B; Cedilak M; Faraho I; Gelone SP
    PLoS One; 2021; 16(9):e0237659. PubMed ID: 34587166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Utility of Lefamulin: If Not Now, When?
    Mercuro NJ; Veve MP
    Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging antibiotics for community-acquired pneumonia.
    Liapikou A; Cilloniz C; Palomeque A; Torres T
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):221-231. PubMed ID: 31657962
    [No Abstract]   [Full Text] [Related]  

  • 34. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
    Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
    JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
    Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia.
    Adhikary S; Duggal MK; Nagendran S; Chintamaneni M; Tuli HS; Kaur G
    Curr Pharmacol Rep; 2022; 8(6):418-426. PubMed ID: 35811574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis.
    Wicha WW; Marbury TC; Dowell JA; Crandon JL; Leister C; Ermer J; Gelone SP
    Pharmacotherapy; 2021 May; 41(5):451-456. PubMed ID: 33797776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96 h after the first dose.
    Powell D; Donato A
    Ann Intern Med; 2020 Feb; 172(4):JC22. PubMed ID: 32066155
    [No Abstract]   [Full Text] [Related]  

  • 39. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
    Zhang L; Wicha WW; Bhavnani SM; Rubino CM
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Antibiotic for Community-Acquired Bacterial Pneumonia.
    Aschenbrenner DS
    Am J Nurs; 2019 Dec; 119(12):20-21. PubMed ID: 31764045
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.